Clinical Trial Update: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating GC012F in relapsed/refractory multiple myeloma is currently recruiting, sponsored by Gracell Biotechnologies (Shanghai) Co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GC012F

Snippet

Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING